Pakistan-China pharma ties under CPEC 2.0

Key Takeaways

• In September 2025, Mabwell and Searle reported DRAP marketing authorization for denosumab biosimilars 9MW0311 and 9MW0321 — Pakistan’s first denosumab biosimilar approvals.
• Mabwell framed Pakistan as a Belt and Road partner with roughly 240 million people and said Searle would support local fill-finish and commercialization.
• In May 2026, Reuters reported a China-Pakistan joint statement to advance high-quality CPEC development and welcome third-party participation.
• CPEC investment figures cited in a PR Newswire/CGTN release ($25.9 billion; 260,000 jobs) describe corridor economics, not a verified pharmaceutical megadeal ledger.

Pakistan-China pharma cooperation at a glance

Field	Detail
Diplomatic frame	May 2026 joint statement: deepen partnership; promote high-quality CPEC
CPEC status (wire)	Described as upgraded to CPEC 2.0; five pillars including innovation and livelihood
Concrete product path	Mabwell denosumab 9MW0311 / 9MW0321 — DRAP authorized Sept 2025
Local partner	The Searle Company Limited (PSX: SEARL); fill-finish + commercialization
China origin status	9MW0311 NMPA-approved 28 Mar 2023; 9MW0321 NMPA-approved 29 Mar 2024
Commercial follow-through	Mabwell reported first overseas denosumab commercial shipment Dec 2025
Market sizing claim	Frost & Sullivan RANKL mAb osteoporosis market $1.317B in 2024 (company-cited)

What did China and Pakistan actually agree on CPEC in May 2026?

The verifiable diplomatic signal is a joint statement, not a pharmaceutical annex. On 26 May 2026, Reuters reported from Karachi that China and Pakistan reached a “new broad consensus” on deepening their strategic partnership after Prime Minister Shehbaz Sharif’s visit to Beijing.

According to that Reuters account of the joint statement, the countries agreed to promote “high-quality development” of the China-Pakistan Economic Corridor and to welcome third-party participation in its development. That language matters for market analysts: it keeps CPEC open as a multi-party investment platform rather than a closed bilateral industrial list.

See Reuters’ 26 May 2026 report on the China-Pakistan joint statement.

How is CPEC 2.0 described in allowlisted wire copy?

A 26 May 2026 PR Newswire release carrying CGTN reporting described CPEC as a Belt and Road flagship upgraded to “version 2.0,” focused on five pillars: growth, livelihood enhancement, innovation, green development, and openness. The same release said the corridor had injected more than $25.9 billion in total investment into Pakistan’s economy and created 260,000 jobs.

It also repeated trade hierarchy claims: China as Pakistan’s largest trading partner for 11 consecutive years, largest import source, second-largest export destination, and largest FDI source, attributed to China’s Ministry of Commerce. Those figures are macroeconomic context for pharma market entry — they do not, by themselves, prove a new CPEC pharmaceutical project pipeline.

Primary wire: PR Newswire / CGTN release on China-Pakistan ties and CPEC 2.0 (26 May 2026).

What is the strongest verified China-Pakistan pharma commercial proof point?

The clearest product-level disclosure is Mabwell’s September 2025 DRAP win with Searle. Mabwell (688062.SH) and The Searle Company Limited said two denosumab injections — 9MW0311 (60 mg; Prolia biosimilar pathway) and 9MW0321 (120 mg; XGEVA biosimilar pathway) — received DRAP marketing authorization.

The companies called this Pakistan’s first regulatory approval for a denosumab biosimilar and Mabwell’s first overseas marketing authorization. Mabwell said it had earlier licensed Searle for local fill-finish and commercialization in Pakistan and explicitly positioned Pakistan as a Belt and Road partner with a population of about 240 million.

Full disclosure: Mabwell’s 5 September 2025 PR Newswire release on Pakistan denosumab approvals.

How do China NMPA origins connect to Pakistan market access?

Mabwell’s Pakistan story is an export of China-approved biologics, not a greenfield molecule invented for CPEC. Per the September 2025 release:

• 9MW0311 received NMPA marketing approval on 28 March 2023 for postmenopausal osteoporosis at high fracture risk.
• 9MW0321 received NMPA approval on 29 March 2024 as China’s first approved XGEVA biosimilar, for unresectable giant cell tumor of bone in adults and skeletally mature adolescents (≥45 kg).
• The company cited Frost & Sullivan data putting the global RANKL monoclonal antibody osteoporosis market at $1.317 billion in 2024.

In May 2026, Mabwell separately said NMPA approved a supplemental application for MAIWEIJIAN (9MW0321) covering bone metastases from solid tumors and multiple myeloma — and restated that Pakistan registration and supply were already underway. That sequence shows China-label expansion and overseas commercialization running in parallel, which is the practical market pattern APAC planners should model.

See Mabwell’s 20 May 2026 PR Newswire on NMPA supplemental indications for MAIWEIJIAN.

What does local fill-finish change for Pakistan’s pharma market structure?

Searle is not a passive importer in the disclosed structure. Mabwell said the licensing deal covers local fill-finish and commercialization. Searle, founded in 1965, is described as operating eight manufacturing facilities including a dedicated biotechnology plant, with exports spanning more than 20 countries.

For market analysis, that structure matters more than corridor slogans:

• Regulatory risk sits with DRAP authorization and ongoing pharmacovigilance.
• Manufacturing risk sits with technology transfer, fill-finish quality systems, and cold-chain biologics handling.
• Commercial risk sits with Pakistani reimbursement, tendering, and physician adoption versus originator denosumab where available.

Mabwell later said its first overseas commercial shipment of denosumab had started, with marketing applications also filed in markets such as Jordan, Egypt, and Brazil — evidence that Pakistan is a beachhead in a broader emerging-market roll-out, not an isolated CPEC one-off. See Mabwell’s 16 December 2025 PR Newswire on the first overseas denosumab shipment.

How should APAC investors read “pharma under CPEC 2.0”?

The accurate synthesis from allowlisted sources is layered, not linear. Diplomatic CPEC language in May 2026 creates political cover and third-party participation optics. Separately, Chinese innovators are using Pakistan’s DRAP pathway plus local partners to commercialize China-approved biologics under a Belt and Road narrative.

That is a real market pattern — China originator/biosimilar capacity meeting Pakistan demand and manufacturing partners — but it is not the same as a published CPEC pharmaceutical master investment schedule with named plants, dollar tranches, and completion dates. Analysts who conflate the two will overstate corridor specificity and understate DRAP/partner execution risk.

Related NovaPharma APAC context on regional partnership and discovery capacity includes coverage of Chinese AI-drug alliances and broader APAC market sizing themes already on the site.

What remains unproven

Several claims circulating in secondary tips should stay out of the verified ledger:

• No allowlisted primary reviewed here publishes a dedicated CPEC 2.0 pharmaceutical project list with committed CAPEX by product class.
• No DRAP gazette extract was independently reproduced in this brief; product status is taken from company wire disclosures.
• Population, market-potential, and RANKL market-size figures are company-cited (or ministry-attributed via wire) and should be treated as directional, not audited NovaPharma estimates.
• Historical vaccine fill-finish episodes (for example older CanSino-related reporting) are not evidence of a 2026 CPEC biologics industrial park.

What is solid enough for an APAC market brief: May 2026 CPEC high-quality-development diplomacy; September 2025 Mabwell-Searle DRAP denosumab authorizations; subsequent commercial shipment and China-label expansion disclosures.

Related NovaPharma coverage

• Insilico Medicine alliance with Bora Pharmaceuticals
• Drug discovery technology market size outlook
• TGA Australia drug approval context

Frequently Asked Questions

Primary Sources

1. Reuters — China, Pakistan reach new broad consensus on boosting ties (26 May 2026)
2. PR Newswire / CGTN — China-Pakistan ties and CPEC 2.0 (26 May 2026)
3. PR Newswire — Mabwell / Searle Pakistan denosumab DRAP approvals (5 Sept 2025)
4. PR Newswire — Mabwell first overseas denosumab commercial shipment (16 Dec 2025)
5. PR Newswire — Mabwell NMPA supplemental indications for MAIWEIJIAN (20 May 2026)